Trevi Therapeutics, Inc. (TRVI) › Operating IncomeTrevi Therapeutics, Inc. (TRVI) — Operating IncomeAnnual figures by fiscal year, from SEC filings.2018: -$18.41M2019: -$26.64M2020: -$32.49M2021: -$32.48M2022: -$29.91M2023: -$33.92M2024: -$51.52M2025: -$49.33M-$49.33M2018Operating Income (USD)2025Fiscal YearOperating IncomeChange YoY2025-$49.33M+4.3%2024-$51.52M-51.9%2023-$33.92M-13.4%2022-$29.91M+7.9%2021-$32.48M+0.0%2020-$32.49M-21.9%2019-$26.64M-44.7%2018-$18.41M—Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share